Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy

Antiviral Therapy

Volumn 15, Issue 3 PART B, 2010, Pages 471-475

  Yeh, Chau Ting ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; DNA POLYMERASE; ENTECAVIR; HEPATITIS B VACCINE; LAMIVUDINE; MUTANT PROTEIN; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; HEPATITIS B SURFACE ANTIGEN; NUCLEOSIDE; NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG POTENCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; REVIEW; STRUCTURAL GENE; VIRUS MUTANT; VIRUS MUTATION; VIRUS REACTIVATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; MOUSE; MUTATION; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MICE; MUTATION; NUCLEOSIDES; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77953441846     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1552     Document Type: Review

References (50)

1. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68. (Pubitemid 28304879)
2. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816. (Pubitemid 36245757)
3. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. (Pubitemid 43357804)
4. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588. (Pubitemid 350294224)
5. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
6. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992; 267:22414-22420.
7. Severini A, Liu XY, Wilson JS, Tyrrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy- 3′-thiacytidine. Antimicrob Agents Chemother 1995; 39:1430-1435.
8. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
9. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009; 49 Suppl 5:S112-S121.
10. Leemans WF, Ter Borg MJ, de Man RA. Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther 2007; 26 Suppl 2:171-182.
11. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 Suppl 5:S174-S184.
12. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514.
13. Reynaud L, Carleo MA, Talamo M, Borgia G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag 2009; 5:177-185.
14. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180. (Pubitemid 30452590)
15. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633. (Pubitemid 28081083)
16. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263. (Pubitemid 29489740)
17. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
18. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572.
19. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273. (Pubitemid 34116979)
20. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
21. Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs 2009; 69:1003-1033.
22. Delaney WE, IV, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77:11833-11841.
23. Warner N, Locarnini S, Kuiper M, et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007; 51:2285-2292. (Pubitemid 47047302)
24. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61:766-768. (Pubitemid 351426057)
25. Hollinger FB. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat 2007; 14 Suppl 1:11-15. (Pubitemid 47624107)
26. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006; 78 Suppl 1:S52-S55. (Pubitemid 43993466)
27. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008; 13:439-447. (Pubitemid 352016737)
28. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'fingers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299:88-99.
29. Villet S, Billioud G, Pichoud C, et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009; 136:168-176.
30. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001; 8:237-247. (Pubitemid 32511107)
31. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 2003; 23: 5-20.
32. Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131:1253-1261. (Pubitemid 44515103)
33. Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudinetreated patients experiencing HBsAg seroclearance. Gastroenterology 2007; 132:543-550.
34. Besisik F, Karaca C, Akyüz F, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003; 38:506-510. (Pubitemid 36399255)
35. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16:131-133. (Pubitemid 34062194)
36. Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49:1483-1491.
37. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133:1445-1451. (Pubitemid 350047463)
38. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48:923-931.
39. Chen CH, Wang JH, Lee CM, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 2006; 11:771-778. (Pubitemid 44497172)
40. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48:747-755.
41. Fung J, Lai CL, Yuen JC, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007; 12:41-46. (Pubitemid 46340424)
42. Pellicelli AM, Barbaro G, Francavilla R, et al. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: A retrospective, multicenter, nonrandomized, open-label study. Clin Ther 2008; 30:317-323. (Pubitemid 351474382)
43. Tatti KM, Korba BE, Stang HL, et al. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antiviral Res 2002; 55:141-150.
44. Jacob JR, Korba BE, Cote PJ, et al. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res 2004; 63:115-121. (Pubitemid 39061776)
45. Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009; 49 Suppl 5:S122-S128.
46. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48:88-98. (Pubitemid 351975534)
47. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther 2008; 13:875-879.
48. Kekulé AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990; 343:457-461. (Pubitemid 20065231)
49. Lauer U, Weiss L, Hofschneider PH, Kekulé AS. The hepatitis B virus pre-S/S(t) transactivator is generated by 3′ truncations within a defined region of the S gene. J Virol 1992; 66:5284-5289.
50. Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 2009; 14:249-261.